Literature DB >> 4075304

Attention deficit disorders in adults.

C T Gualtieri, M G Ondrusek, C Finley.   

Abstract

Twenty-two adults who met DSM-III criteria for "Attention Deficit Disorder, Residual Type" (ADD-RT) were evaluated in a series of clinical experiments. Although certain personality and psychological factors typified the ADD-RT group, methylphenidate blood levels, the growth hormone response to methylphenidate, and the brainstem evoked response did not distinguish subjects from matched controls. Male subjects seemed to be a more homogeneous group than female subjects. Socioeconomic status and IQ, but not severity of ADD symptoms, were found to predict outcome. ADD adults seem to be numerous and easy to identify, at least on the basis of symptoms. However, the validity of ADD-RT as a "distinct clinical entity" is open to question.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4075304     DOI: 10.1097/00002826-198512000-00005

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  12 in total

1.  [Methylphenidate in adults with attention-deficit/hyperactivity disorder].

Authors:  M Kösters; S Weinmann; T Becker
Journal:  Nervenarzt       Date:  2007-09       Impact factor: 1.214

2.  Methylphenidate-induced improvements of various measures of attention in adults with attention deficit hyperactivity disorder.

Authors:  O Tucha; L Mecklinger; R Laufkötter; H E Klein; S Walitza; K W Lange
Journal:  J Neural Transm (Vienna)       Date:  2006-08-08       Impact factor: 3.575

Review 3.  Stimulant drugs.

Authors:  P J Santosh; E Taylor
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

4.  Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis.

Authors:  Xavier Castells; Josep Antoni Ramos-Quiroga; David Rigau; Rosa Bosch; Mariana Nogueira; Xavier Vidal; Miguel Casas
Journal:  CNS Drugs       Date:  2011-02       Impact factor: 5.749

Review 5.  Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.

Authors:  Kim Boesen; Asger Sand Paludan-Müller; Peter C Gøtzsche; Karsten Juhl Jørgensen
Journal:  Cochrane Database Syst Rev       Date:  2022-02-24

6.  European clinical guidelines for hyperkinetic disorder -- first upgrade.

Authors:  Eric Taylor; Manfred Döpfner; Joseph Sergeant; Philip Asherson; Tobias Banaschewski; Jan Buitelaar; David Coghill; Marina Danckaerts; Aribert Rothenberger; Edmund Sonuga-Barke; Hans-Christoph Steinhausen; Alessandro Zuddas
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

Review 7.  Drug therapy for adults with attention-deficit hyperactivity disorder.

Authors:  Timothy E Wilens
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.

Authors:  Michael Rösler; Roland Fischer; Richard Ammer; Claudia Ose; Wolfgang Retz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-01-22       Impact factor: 5.270

9.  Treatment of adult ADHD: is current knowledge useful to clinicians?

Authors:  Terje Torgersen; Bjørn Gjervan; Kirsten Rasmussen
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

10.  Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder.

Authors:  Joseph Biederman; Eric O Mick; Craig Surman; Robert Doyle; Paul Hammerness; Evan Michel; Jessica Martin; Thomas J Spencer
Journal:  BMC Psychiatry       Date:  2007-09-14       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.